Stable Pharmaceutical Compositions Comprising a Pyrimidine-Sulfamide
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application 12/066,448, filed Mar 19, 2008. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,648,249 | Stable Pharmaceutical Compositions Comprising a Pyrimidine-Sulfamide In force · Medium confidence | Actelion Pharmaceuticals Ltd. | In force | Medium confidence | ||
| US 9,265,762 | Stable Pharmaceutical Compositions Comprising a Pyrimidine-Sulfamide In force · High confidence | Actelion Pharmaceuticals Ltd. | In force | High confidence | ||
| US 8,367,685 | Stable Pharmaceutical Compositions Comprising a Pyrimidine-Sulfamide In force · High confidence | Actelion Pharmaceuticals Ltd. | In force | High confidence | ||
| US 10,117,870 | Stable Pharmaceutical Compositions Comprising a Pyrimidine-Sulfamide Term ended Term ended Sep 11, 2026 · High confidence | Actelion Pharmaceuticals Ltd. | Term ended | Term ended Sep 11, 2026 | High confidence | |
| US 10,946,015 | Stable Pharmaceutical Compositions Comprising a Pyrimidine-Sulfamide Term ended Term ended Sep 11, 2026 · High confidence | Actelion Pharmaceuticals Ltd. | Term ended | Term ended Sep 11, 2026 | High confidence | |
| Application 12/066,448 | Stable Pharmaceutical Compositions Comprising a Pyrimidine - Sulfamide Abandoned Abandoned Jan 23, 2012 | Actelion Pharmaceuticals Ltd. | Abandoned | Abandoned Jan 23, 2012 |
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Actelion Pharmaceuticals Ltd.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.